Alnylam Pharmaceuticals (ALNY) Payables (2009 - 2026)

Alnylam Pharmaceuticals' Payables history runs 18 years deep, the most recent figure standing at $126.6 million for Q1 2026.

• Quarterly Payables fell 41.24% year-over-year to $126.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $126.6 million (down 41.24% YoY) and the FY2025 annual result came in at $115.7 million, down 36.49% from the prior year.
• Payables was $126.6 million for Q1 2026 at Alnylam Pharmaceuticals, up from $115.7 million in the prior quarter.
• Across five years, Payables topped out at $238.8 million in Q3 2025 and bottomed at $40.6 million in Q3 2022.
• A 5-year average of $107.2 million and a median of $74.0 million in 2024 frame the typical range for Payables.
• Annual changes were most pronounced in 2023 — Payables tumbled 43.4% — and 2025, when it soared 237.32%.
• Alnylam Pharmaceuticals' Payables stood at $98.1 million in 2022, then slumped by 43.4% to $55.5 million in 2023, then jumped by 228.2% to $182.2 million in 2024, then tumbled by 36.49% to $115.7 million in 2025, then rose by 9.43% to $126.6 million in 2026.
• Business Quant data shows ALNY's Payables at $126.6 million in Q1 2026, $115.7 million in Q4 2025, and $238.8 million in Q3 2025.